Objective: Cognitive deficits are common in epilepsy, though the impact of epilepsy on cognition in older adults is understudied. This study aimed to characterize cognition in older adults with epilepsy compared with healthy older adults and identify potential risk factors for impairment. Methods: Thirty-eight older adults with epilepsy and 29 healthy controls completed a comprehensive neuropsychological battery, as well as measures of depression and anxiety. Chart review for current medications, seizure history, and neuroimaging was also completed. To compare cognitive performance between groups, ANOVA was used, and linear regression identified predictors of impairment among the group with epilepsy. Results: Patients with epilepsy performed worse across nearly all cognitive domains, and were clinically impaired (i.e., ≥1.5 SD below mean) on more individual tests when compared with controls, including a subset of patients with epilepsy with normal MRIs. For all patients with epilepsy, taking a greater number of antiepileptic drugs was associated with poorer language and visuospatial abilities, and higher anxiety was associated with poorer visual memory.
Introduction
The incidence of epilepsy in adults increases significantly with advancing age, particularly in those over the age of 60 years [1] . Compared with healthy controls, older adults with epilepsy demonstrate deficits across numerous cognitive domains [2] [3] [4] . Older adults with epilepsy also demonstrate deficits when compared with individuals with known cognitive impairment. For example, Griffith et al. [4] found that older adults with epilepsy demonstrated worse performance on aspects of the Dementia Rating Scale (DRS), a measure of global cognitive functioning, and letter fluency when compared with individuals with amnestic mild cognitive impairment (MCI). Moreover, they performed similarly to those with amnestic MCI on all other measures [4] .
The relationship between cognitive decline and epilepsy characteristics is complex and still incompletely understood. The available literature has demonstrated that the duration of seizure disorder and age of onset correlated with memory performance, with longer seizure duration associated with worse performance, and a later age of onset associated with better performance [2] . Individuals with refractory temporal lobe epilepsy for more than 30 years also demonstrated lower full scale IQ scores compared with those with shorter duration of illness [5] . The negative impact of antiepileptic drugs (AEDs), particularly AED polytherapy, on cognition has been cited consistently. Individuals on AED monotherapy have performed worse than controls on measures of conceptualization and verbal learning. Moreover, when compared with AED monotherapy and healthy controls, polytherapy was associated with worse overall performance on the DRS as well as poorer performance on the DRS subtests of attention, initiation/perseveration, and memory, and delayed recall on a story memory task [2] . Antiepileptic drug polytherapy has also surfaced as a significant predictor of poorer performance on additional tasks of attention, executive function, and memory [3] . In addition, patients taking AED polytherapy had worse cognitive performance compared with those with MCI taking a cholinesterase inhibitor [4] .
Previous work has also found that older adults with epilepsy endorsed higher levels of depression than controls, and that depression was negatively correlated with performance on tasks of memory, fluency, and global cognition [2] . To our knowledge, the relationship between anxiety and cognitive function has not been systematically examined in the older adult population with epilepsy.
Through a comprehensive neuropsychological battery, the current study aimed to expand on previous work by more precisely characterizing the nature and prevalence of cognitive deficits in older adults with epilepsy. We also sought to identify specific risk factors for cognitive impairment within this population by examining the impact of epilepsyrelated factors (i.e., age of onset, seizure frequency in past month, total AEDs, AEDs with well-established cognitive side effects), as well as psychiatric factors (i.e., depression and anxiety) on cognitive performance. Our study extends previous work through the inclusion of anxiety as a potential risk factor for cognitive impairment and by examination of the impact of specific AEDs on cognition, particularly those with known cognitive side effects. A greater understanding of the nature of cognitive deficits among older adults with epilepsy, as well as the associated risk factors, would help guide treatment selection in this population.
Methods

Participants
This research was approved by the Rhode Island Hospital Institutional Review Board, and all study participants provided written informed consent prior to initiating study procedures. Thirty-eight adults with epilepsy and twenty-nine cognitively intact adults, 55 years of age or older, participated in the current study. Patients with epilepsy were recruited through a hospital-based neurology practice, and controls were recruited through community advertising. Individuals in the group with epilepsy had documented epilepsy as diagnosed by a neurologist. Healthy controls had no history of seizures or epilepsy and no current cognitive complaints. Exclusion criteria for both groups included a history of intellectual disability or other serious developmental disorder; progressive CNS disorders (e.g., dementia, demyelinating conditions, Parkinson's disease); significant hepatic, renal, or cardiopulmonary condition; brain injury beyond concussion; severe psychiatric conditions (e.g., schizophrenia, bipolar disorder); and substance abuse disorders within the past 6 months.
Measures
Emotional functioning
All participants completed the Beck Depression Inventory-II (BDI-II) [6] and the State-Trait Anxiety Inventory (STAI) [7] . A higher score on the BDI-II is indicative of greater levels of depressive symptomatology. Total score on the trait component of the STAI was computed to determine levels of chronic anxiety, with higher scores reflective of greater levels of anxiety.
Epilepsy characteristics
A comprehensive history was taken for each older adult with epilepsy. Specific characteristics examined in the current study included: age of first seizure, patient's reported seizure frequency over the past month, and total number of currently prescribed AEDs. Antiepileptic drugs were further categorized based on the presence/absence of known cognitive side effects. Medications with the most clinical evidence for cognitive side effects included: topiramate, zonisamide, phenobarbital, primidone, phenytoin, carbamazepine, divalproex, clonazepam, and lorazepam. Medications considered lacking robust clinical evidence for adverse cognitive side effects included: levetiracetam, lamotrigine, oxcarbazepine, pregabalin, gabapentin, and lacosamide [8] [9] [10] .
Additional medications among patients with epilepsy included those for managing typical medical conditions among older adults (e.g., hypertension, acid reflux), as well as a small number of antidepressant and anxiolytic medications. The control group had a similar medication profile. We would expect the burden of these medications on cognition to be minimal.
Neuropsychological tests
All study participants completed a comprehensive battery of wellestablished neuropsychological tests including:
Global cognition
Mini-Mental State Examination (MMSE) [11] . This is brief screening measure of cognition that assesses orientation, basic attention, working memory, learning, naming, construction, comprehension, and repetition. The maximum score is 30, with scores below 24 suggesting cognitive impairment.
Mattis Dementia Rating Scale-2 (DRS) [12] . The DRS is a screening test designed to assess cognition in older adults. It consists of five subscales-Attention, Initiation/Perseveration, Construction, Conceptualization, and Memory. The maximum score is 144, with lower scores indicating greater cognitive impairment, and scores less than or equal to 124 suggesting dementia.
Verbal memory
Hopkins Verbal List Learning Test-Revised [13] . Participants are asked to learn and remember a list of 12 words over the course of three trials. After a 20-minute delay during which other tasks are completed, participants are asked to recall as many words from the list as possible. Total learning and delayed recall are recorded.
Verbal Paired Associates [14] . Participants are asked to learn 14 word pairs over the course of 4 trials. Some pairs are congruent (e.g., sky-cloud), while others are incongruent (e.g., tree-luck). They are given the first word of the pair and are asked to provide the other word. After a 30-minute delay, they are again asked to provide the second word of the pairing. Total learning and delayed recall are recorded.
Visual memory
Brief Visuospatial Memory Test-Revised [15] . Participants are shown a 2 × 3 array of 6 simple geometric designs. They are given 10 s to study the display and are then asked to draw what they can recall as accurately as possible and in the correct location. Learning over 3 trials and free recall after a 20-minute delay are recorded.
Attention/psychomotor speed
Trail Making Test-A [16] . Participants are asked to connect a series of 25 numbered dots in ascending order as quickly as they can (e.g., 1-2-3, etc.). Time to completion is recorded.
Digit Symbol Coding [17] . Participants are asked to transpose a coded sequence. They are provided with a key at the top of the page (e.g., a "1" means "+") and an array of numbers below, and are asked to draw the corresponding symbol. Total number of correct responses in 120 s is recorded.
Executive function
Trail Making Test-B [16] . This test adds a set-shifting component to Trail Making Test-A and requires participants to alternate between numbers and letters in ascending order (e.g., 1-A-2-B, etc.). Time to completion is recorded.
Controlled Oral Word Association [18] . Participants are asked to generate as many words as they can that begin with a given letter. A total of three letters are given. Participants have 60 s for each letter and cannot use proper nouns or numbers, or provide different endings to a root word already given.
Rey-O Complex Figure-Boston Qualitative Scoring System: Organization [19] . Participants are asked to copy a figure that includes multiple components. An organization score is obtained through the use of a scoring method that evaluates the approach taken to complete the drawing.
Language
Boston Naming Test [20] . This test is a measure of confrontation naming. Participants are shown pictures and asked to name the depicted item. Item difficulty increases from high-frequency objects to lower-frequency objects. Total correct is recorded.
Animal Fluency [18] . This test is a measure of semantic verbal fluency. Participants name as many different kinds of animals as they can in 60 s.
Visuospatial
Rey-O Complex Figure-Boston Qualitative Scoring System: Copy Presence and Accuracy [19] . The copy of the complex figure is scored for the inclusion, accuracy, and placement of all aspects.
Judgment of Line Orientation [21] . This is a task of visuoperception in which participants are asked to match two free standing lines to a reference point of 11 lines equally spaced in a semicircle in terms of angle and direction.
Analyses
With the exception of the MMSE and DRS, raw scores were corrected for age and, when possible, gender and education, using well established normative data that are consistent with standard clinical practice in neuropsychology. Specific tests corrected for age, education, and gender included: Trail Making Test A & B, Controlled Oral Word Association, Boston Naming Test, and Animal Fluency [22] . All scores were then converted into t-scores to facilitate interpretation. Composite scores were created for each cognitive domain by averaging all the scores within each domain (attention/psychomotor speed, executive function, language, visual memory, verbal memory, visuospatial skills). Frequency of cognitive impairment was determined by calculating the percentage of individuals whose domain scores were 1.5 standard deviations below the normative mean scores, as is consistent in clinical practice. Independentsample t-test and chi-square analyses were used to examine group differences in demographic and clinical characteristics.
For the primary analyses, ANOVA was used to examine differences in neuropsychological test performance for all measures except the MMSE and DRS, for which ANCOVA (controlling for age) was used. Linear regression was then used to identify potential risk factors for cognitive impairment with the group with epilepsy. For all regression analyses, the cognitive domain served as the dependent variable and the predictors (i.e., age of onset, seizure frequency in past month, total AEDs, depression, and anxiety) were entered into the model simultaneously.
Secondary analyses were conducted to determine if brain lesions could explain cognitive impairments. Cognitive performance across domains was compared between a subgroup of the above-described group with epilepsy without brain lesions (n = 21) and the control group using ANOVA. Table 1 presents the demographic and clinical characteristics of the groups. When compared with controls, individuals in the group with epilepsy were significantly older and endorsed higher levels of depression and trait anxiety. The control group had a significantly greater percentage of females. These differences were not controlled for in further analyses as the use of normative data corrected for age and, in many cases, gender. In addition, depression and anxiety were considered to be characteristic of epilepsy, and follow-up analyses were planned to determine the impact of these variables on cognition. There were no differences in education between the two groups (p N .05). Table 2 presents full epilepsy characteristics including location, lateralization, etiology, and medications. More than half of the participants were treated with AED polytherapy, and nearly half were on one or more medications that have been associated with cognitive side effects. 
Results
Demographic and clinical characteristics
Group differences in neuropsychological test performance
Prevalence of cognitive impairment
Cognitive impairment was found in all domains of cognitive function for the group with epilepsy, including 39.5% with impairment in visual memory, 23.7% each in attention and executive function, 18.4% in visuospatial skills, and 15.8% for both verbal memory and language.
Epilepsy subgroup analyses
To address whether cognitive difficulties could be explained by brain lesions, follow-up analyses examined performance of a subset of 21 individuals with epilepsy who did not demonstrate any brain lesions on MRI. Demographic comparison between the two groups indicated that similar to the overall findings, the group with nonlesional epilepsy was significantly older than the control group [t(33.38) = 3. Examination of individual predictors revealed that the total number of AEDs predicted language and visuospatial performance, with a greater number of AEDs associated with worse performance in those domains. Follow-up ANOVA was conducted to examine whether there were differences in cognitive performance between patients on zero, one, or two or more AEDs with cognitive side effects. Results were nonsignificant for both language [F(2, 35) = 2.79, p = .08] and visuospatial [F(2, 35) = 2.60, p = .09] performance. Anxiety significantly predicted visual memory performance (p = .03). See Table 4 for regression coefficients for significant omnibus tests.
Discussion
In this analysis, older adults with epilepsy performed worse on neuropsychological testing across nearly all domains of cognitive function when compared with older adults without epilepsy. Rates of cognitive impairment were high among this group, particularly for visual memory, attention, and executive function. The current findings expand on the literature [2] [3] [4] by demonstrating a wide range of cognitive deficits on a comprehensive neuropsychological battery among older adults with epilepsy compared with controls. This study further elucidates risk factors for cognitive deficits and examines the contribution of epilepsy characteristics and psychological factors to neuropsychological test performance in older adults with epilepsy.
We found that the total number of AEDs was associated with worse language and visuospatial performances. Such findings are consistent with previous work showing that AED polytherapy is associated with worse cognitive outcomes [2, 3] . Our follow-up analyses, however, indicated that a greater number of AEDs with known potential for cognitive side effects were not associated with worse performance on cognitive testing, suggesting contribution from other mechanisms or factors. These observations lead us to wonder if the total number of AEDs in use may be a crude marker for the severity of the patient's epilepsy at the time of testing, or even cumulatively over time. In this regard, it may not be the particular AED in use, but rather the total number of AEDs that is germane to reflecting the burden of epilepsy on the patient's cognitive performance. This notion remains speculative based on such modest data as herein. Note. All scores are standardized t-scores based on normative data, unless otherwise noted. Age was controlled for in analyses using raw scores. MMSE = Mini-Mental Status Examination, DRS = Dementia Rating Scale. Depression and anxiety are common among individuals with epilepsy, with the prevalence ranging from 20 to 60% and from 15 to 20%, respectively [23] , though there is limited work examining their contribution to cognitive deficits. In this study, we demonstrated that higher levels of anxiety were related to poorer visual memory scores. This finding is not surprising given the association between anxiety and cognitive function in other elderly samples [24] . However, to our knowledge, this is the first study to demonstrate an independent contribution of anxiety to cognitive performance in older adults with epilepsy. These findings highlight the importance of assessing for anxiety in older adults with epilepsy, since it may go underdiagnosed in this population, as has been demonstrated with depression [25] . Moreover, it will be important for future work to examine the potential impact of treating anxiety on cognitive outcomes.
A striking finding of this study is that even among patients without demonstrated brain lesions, cognitive impairment was still quite prevalent and performance across domains was worse when compared with the control group. It is possible that epilepsy interacts with the aging process or with other medical conditions associated with aging (e.g., hypertension, diabetes) to increase the risk of cognitive decline.
It remains unclear which of the patient's epilepsy characteristics best predict cognitive outcomes. A recent study [26] found that individuals with greater seizure frequency performed more poorly on memory tests. However, these findings were not corroborated by Piazzini et al. [3] who found that seizure etiology and frequency were not related to cognitive function. In the present study, in contrast to our own expectations, seizure severity and age of onset were not associated with cognitive functioning. One potential reason for these negative findings, and perhaps in previous investigations, involves methodological limitations for adequately characterizing the cumulative burden of the patient's condition. The course of epilepsy varies greatly between individuals and over time. It is difficult to capture these differences in one variable, such as seizure frequency or age of onset, particularly when relying on the retrospective report of the patient. Future studies should examine other variables, or combinations of variables, in large samples allowing for detailed subgroup analyses, to try to better characterize the patient's burden of epilepsy over time in relation to cognitive outcomes in this setting.
This study is limited primarily by its relatively small sample size and cross-sectional design which may hinder its generalizability. Larger studies that prospectively follow more diverse samples are needed to further examine possible contributors to cognitive impairment in this population. This could facilitate exploring the role of lifetime burden of epilepsy and help elucidate the relative impact of AED use, epilepsy lateralization, duration/age of onset, and etiologic differences upon cognitive outcomes.
Overall, the current study demonstrated worse cognitive function in older adults with epilepsy, even in those without brain lesions, compared with healthy controls. In addition, AED polypharmacy and anxiety were identified as predictors of some aspects of cognition. This study corroborates past findings, documenting the differences in cognitive performance among older adults with and without epilepsy, and extends this work by further characterizing the nature of cognitive deficits observed among older adults with epilepsy.
In contrast to expectations, AEDs with cognitive side effects did not heighten the risk for cognitive impairment, which suggests that other AED-related mechanisms are likely at play, given the predictive power of the total number of AEDs. The current study identified anxiety as a novel risk factor for cognitive deficits among older adults with epilepsy, and if replicated, suggests that anxiety may be an important treatment target. Future work to further clarify and understand risk factors for cognitive impairment in this population is warranted to optimize treatment and attenuate risk for cognitive decline.
